RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early test of Next-Gen RSV vaccine begins
⭐️ VACCINE ⭐️ OngoingThis early-stage study is testing different versions of a new RSV vaccine made with mRNA technology. It will involve 240 healthy adults aged 18-49 to check if the vaccines are safe and if they trigger a good immune response against the virus. Participants will receive one shot an…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION
Phase: PHASE1 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 30, 2026 14:33 UTC
-
New Two-in-One shot aims to shield seniors from dangerous viruses
⭐️ VACCINE ⭐️ OngoingThis study is testing a new mRNA vaccine designed to protect adults aged 60 and older from two common respiratory viruses: human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). Researchers will give the vaccine to about 1,530 participants to check how safe it is and…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 27, 2026 12:40 UTC